PLSE — Pulse Biosciences Share News
0.000.00%
Last trade - 00:00- $3.25bn
- $3.15bn
- $0.35m
Pulse Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary
Pulse Biosciences Q2 net loss widens, cash position strengthens
Pulse Biosciences Inc expected to post a loss of 36 cents a share - Earnings Preview
Brief: Pulse Biosciences, Inc. Announces Planned Redemption Of Warrants
Chairmen Total Approximately $13.3 Million
Pulse Biosciences records Q1 revenue, but loss widens on higher clinical investment
Brief: Pulse Biosciences Q1 Net Income USD -18.581 Million
Brief: Pulse Biosciences Announces Positive Clinical Data From Npulse Cardiac Catheter System
Brief: Pulse Biosciences Strengthens Executive Leadership Team
Brief: Pulse Biosciences Enrolls First Patients in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation
Brief: Pulse Biosciences Announces Strategic Alignment To Accelerate Cardiac Catheter Program Following Exceptional Long-Term Afib Clinical Data
Brief: Pulse Biosciences To Offer Securities Worth $200 Million
Brief: Pulse Biosciences Says It Enters Equity Distribution Agreement With TD Securities
Pulse Biosciences Q4 revenue rises q-o-q
Brief: Pulse Biosciences Q4 Income From Operations USD -18.253 Million
Brief: Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Pulse Biosciences Announces FDA IDE Approval to Initiate its nPulse Cardiac Catheter Ablation System Study
Brief: Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Pulse Biosciences Q3 net loss widens